Valiant Laboratories Approves Key Director Reappointments and Signals Rs 60 Crore Investment in Subsidiary

<h1>Valiant Laboratories Approves Key Director Reappointments and Signals Rs 60 Crore Investment in Subsidiary</h1>

Valiant Laboratories Limited announced several significant outcomes from its Board of Directors meeting, approving key appointments, corporate restructuring moves, and a substantial investment plan for its wholly-owned subsidiary, Valiant Advanced Sciences Private Limited (VASPL).

The Board approved the re-appointment of Mr. Santosh Vora as Managing Director (MD) for five years, effective February 06, 2027. The appointment follows a recommendation from the Nomination and Remuneration Committee. Additionally, Mrs. Sonal Vira was re-appointed as an Independent Director (ID) for a second term of five consecutive years, effective February 16, 2027.

The company also approved the continuation of Mr. Shantilal Vora's directorship as a Non-Executive Non-Independent Director upon his attainment of age 75, scheduled to take effect from November 05, 2027. All three directors were confirmed not to be debarred from holding office by any authority.

The Board meeting also greenlit the shifting of the Company’s Registered Office. The move involves relocating the address from Mumbai to Plot No L-13, L-28, L-28(Pt), L-29 & L-30 in MIDC Tarapur, Boisar, Palghar, Maharashtra, resulting in a change in jurisdiction from the Registrar of Companies, Mumbai-I to the Registrar of Companies, Mumbai-II (Navi Mumbai). Furthermore, the company approved the opening of a new Corporate Office at 701, Tower B, Embassy 247 Park, LBS Road, Vikhroli (West), Mumbai, which will serve as the administrative and management center.

<h2>Investment in Valiant Advanced Sciences Private Limited</h2>

A major approval announced was the authorization for an additional investment in its subsidiary, VASPL, up to an aggregate amount not exceeding ₹ 60 Crore. This capital infusion is planned through the subscription of 1% Optionally Convertible Redeemable Preference Shares. The proposed investment is intended to meet the working capital requirements and general corporate purposes of VASPL, thereby strengthening its capital base.

VASPL operates in the speciality chemicals sector, manufacturing products such as acetic anhydride, ketene, and diketene derivatives. Although the investment will be made through a cash consideration, the transaction maintains that Valiant Laboratories Limited's shareholding percentage in VASPL will remain unchanged, as it is already a wholly owned subsidiary of the Company.

<h2>VASPL Financial Snapshot</h2>

As part of the disclosure related to the investment opportunity, the following details regarding VASPL were provided:


In addition to the financial figures, VASPL has been engaged in manufacturing specialty chemicals since its incorporation on July 08, 2022. The company remains a related party to Valiant Laboratories Limited and the proposed investment is considered to be at arm's length.

VALIANTLAB Stock Price Movement​

Today, Valiant Laboratories Limited shares edged higher to close at ₹67.81, gaining 4.99% in post-market trading. The stock saw a total volume of 26,353 shares changing hands during the session.